`Filed: July 30, 2015
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`________________
`
`COALITION FOR AFFORDABLE DRUGS VI LLC
`
`Petitioner,
`
`v.
`
`CELGENE CORPORATION
`
`Patent Owner
`________________
`
`Case IPR2015-01096
`
`Patent 6,315,720
`________________
`
`
`
`PATENT OWNER PRELIMINARY RESPONSE
`PURSUANT TO 35 U.S.C. § 313 and 37 C.F.R. § 42.107
`
`
`
`
`
`04841.00006/7046102.1
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`TABLE OF CONTENTS
`
`Page
`
`I.
`
`INTRODUCTION ........................................................................................... 1
`
`II.
`
`BACKGROUND ............................................................................................. 3
`
`A.
`
`B.
`
`The Challenge of Protecting A Fetus From A Teratogenic
`Drug While Allowing A Patient Access to Its Efficacy........................ 5
`
`Previous Attempts to Control
`Access to Other Drugs Were Unsuccessful ........................................ 11
`
`C.
`
`The ’720 Patent ................................................................................... 14
`
`III. ARGUMENT ................................................................................................. 18
`
`A.
`
`The Petition Should Be Denied Because
`CFAD Has Failed To Show A Reasonable Likelihood
`That The Challenged Claims Are Unpatentable ................................. 19
`
`1.
`
`CFAD’s Expert Declaration Is
`Entitled to “little or no weight” ................................................. 19
`
`(a) Dr. Fudin Is Not A POSA ............................................... 19
`
`(b) Dr. Fudin’s Opinions Are
`Unsupported, Verbatim Recitations of
`CFAD’s Conclusory Arguments .................................... 21
`
`2.
`
`Ground 1: Claims 1-32 Are
`Not Anticipated by the July 1998 Thalomid PI ........................ 22
`
`(a)
`
`Legal Standards .............................................................. 22
`
`(b) The July 1998 Thalomid PI
`Does Not Disclose Each Claim Limitation,
`Either Expressly Or Inherently ....................................... 23
`
`i.
`
`Claim 1 ................................................................. 24
`
`1)
`
`Element 1(b) – “defining a set of
`information to be obtained from said
`
`04841.00006/7046102.1
`
`- i -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`2)
`
`3)
`
`4)
`
`patient, which information is
`probative of the risk that said adverse
`side effect is likely to occur if said
`drug is taken by said patient” ..................... 24
`
`Element 1(c) – “in response to said
`information set, assigning said patient
`to at least one of said risk groups and
`entering said risk group assignment in
`said medium” ............................................. 25
`
`Element 1(d) – “based upon said
`information and said risk group
`assignment, determining whether the
`risk that said adverse side effect is
`likely to occur is acceptable.” .................... 27
`
`Element 1(e) – “upon a determination
`that said risk is acceptable, generating
`a prescription approval code to be
`retrieved by said pharmacy before
`said prescription is filled.” ......................... 28
`
`ii.
`
`Dependent Claims 2-27 ........................................ 29
`
`1)
`
`2)
`
`Claim 5 – “Wherein said risk group
`assignment and said informed consent
`is verified by said prescriber at the
`time that said patient is registered in
`said computer readable storage
`medium.” .................................................... 30
`
`Claim 6 – “wherein said risk group
`assignment and said informed consent
`is transmitted to said computer
`readable storage medium by facsimile
`and interpreted by optical character
`recognition software.” ................................ 32
`
`3)
`
`Claim 9 – “Wherein said diagnostic
`testing is probative of the
`
`04841.00006/7046102.1
`
`- ii -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`4)
`
`5)
`
`6)
`
`concentration of said drug in a tissue
`of said patient.” .......................................... 33
`
`Claim 10 – “wherein said diagnostic
`testing comprises genetic testing” .............. 35
`
`Claim 15(h) – “entering said second
`set of information in said medium
`before said patient is approved to
`receive said drug” ...................................... 36
`
`Claim 17 – “Wherein said survey is
`conducted telephonically using an
`integrated voice response system.” ............ 37
`
`iii.
`
`Independent Claim 28 and
`Dependent Claims 29-32 ...................................... 37
`
`3.
`
`Ground 2: Claims 1-32 Would
`Not Have Been Obvious Over
`The July 1998 Thalomid PI, Cunningham,
`and the Knowledge of a POSA ................................................. 39
`
`(a)
`
`The Petition Fails To Address
`The Redundancy With The
`2015-01102 and 2015-01103 Petitions ........................... 39
`
`(b) CFAD Fails to Consider the
`Claim Language as a Whole or to
`Perform a Proper Graham Analysis ............................... 41
`
`(c) CFAD Has Not Provided A
`Motivation To Combine the
`July 1998 Thalomid PI and Cunningham ....................... 43
`
`(d) The July 1998 Thalomid PI, Cunningham,
`And The Knowledge Of A POSA
`Fail To Disclose, Teach, Or Suggest
`Key Elements Of The Claimed Inventions ..................... 46
`
`i.
`
`Claim 1(e) and 28(e) – “approval code” .............. 46
`
`04841.00006/7046102.1
`
`- iii -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`ii.
`
`Claim 5 – “Wherein said risk group
`assignment and said informed consent is
`verified by said prescriber at the time that
`said patient is registered in said computer
`readable storage medium.” ................................... 47
`
`iii. Claim 17 – “Wherein said survey is
`conducted telephonically using an integrated
`voice response system.” ....................................... 49
`
`4.
`
`CFAD Fails To Address The Objective Evidence of
`Nonobviousness Regarding the ’720 Patent ............................. 50
`
`(a)
`
`Long-felt Need Further Supports The
`Nonobviousness Of The Claimed Inventions ................. 50
`
`(b) Commercial Success Further Supports The
`Nonobviousness Of The Claimed Inventions ................. 52
`
`(c)
`
`Third-Party Praise And Awards Further Supports
`The Nonobviousness Of The Claimed Inventions ......... 53
`
`(d) Licensing by Others Further Supports The
`Nonobviousness Of The Claimed Inventions ................. 53
`
`(e) Unexpected Results Further Supports The
`Nonobviousness Of The Claimed Inventions ................. 54
`
`B.
`
`C.
`
`The Petition Should Be Denied
`Under 35 U.S.C. §§ 314(a) and 316(b) ............................................... 55
`
`The Petition Should Be Denied
`For Failing To Name All Real Parties-In-Interest .............................. 58
`
`IV. CONCLUSION .............................................................................................. 60
`
`
`04841.00006/7046102.1
`
`- iv -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`I.
`
`INTRODUCTION
`
`IPR2015-01096
`Patent 6,315,720
`
`Pursuant to 35 U.S.C. § 313 and 37 C.F.R. § 42.107(a), Patent Owner
`
`Celgene Corporation (“Celgene”) submits this Preliminary Response to Coalition
`
`For Affordable Drugs VI LLC’s (“CFAD”) Petition for Inter Partes Review (the
`
`“Petition”) of U.S. Patent No. 6,315,720 (the “’720 patent”).
`
`The ’720 patent describes and claims improved methods for delivering a
`
`potentially dangerous drug to a patient (including teratogenic drugs such as
`
`thalidomide) while avoiding the occurrence of adverse side effects (such as birth
`
`defects of the type associated with thalidomide). The inventions were conceived as
`
`part of Celgene’s efforts to significantly improve its existing program for
`
`controlling patient access to thalidomide, which was known as the System for
`
`Thalidomide Education and Prescribing Safety, or S.T.E.P.S.® The improved
`
`program, which Celgene called Enhanced S.T.E.P.S.®, is an embodiment of the
`
`’720 patent and has been used in connection with thalidomide and other potentially
`
`teratogenic pharmaceutical products since 2001. During that time it has
`
`successfully prevented 100% of drug-related birth defects. In fact, the inventions
`
`of the ’720 patent were so successful and innovative that the FDA required other
`
`drug manufacturers to copy Celgene’s patented methods if they wanted to keep
`
`their products on the market, resulting in licenses to several of Celgene’s patents,
`
`including the ’720 patent.
`
`04841-62499/6939746.4
`
`- 1 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`Notwithstanding Celgene’s significant innovation, CFAD has filed the
`
`present Petition as part of a hedge fund investment strategy developed by the real
`
`parties-in-interest (“RPI”). CFAD’s Petition, however, has several fatal defects.
`
`First, CFAD relies heavily on an expert declaration that is entitled to little or
`
`no weight because the declarant is not a person of ordinary skill in the art (POSA),
`
`and because the declaration merely reiterates CFAD’s conclusory arguments.
`
`Second, CFAD’s Ground 1 anticipation argument fails on the merits because
`
`the cited art—the original July 1998 Thalomid® package insert (“July 1998
`
`Thalomid PI,” CFAD’s Ex. 1006)—does not disclose each and every element of
`
`the ’720 patent claims. Indeed, CFAD admits that many of the claim limitations of
`
`the ’720 patent are not expressly disclosed in the July 1998 Thalomid PI. Instead,
`
`CFAD argues that the missing limitations are inherently disclosed, but those
`
`limitations are not “necessarily present,” and CFAD fails to explain how or why
`
`they allegedly are. Moreover, the July 1998 Thalomid PI is, at best, cumulative to
`
`other references that were extensively considered by the Examiner during
`
`prosecution. Ground 1 does not warrant an IPR trial of the ’720 patent.
`
`Third, CFAD’s Ground 2 obviousness argument fails on the merits because
`
`none of the cited references disclose, teach, or suggest all elements of the
`
`challenged claims. CFAD’s proposed modifications to, and combinations of, the
`
`alleged prior art disclosures are driven entirely by hindsight and supported only by
`
`04841.00006/7046102.1
`
`- 2 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`conclusory assertions by CFAD’s declarant, who merely parrots the arguments in
`
`the Petition. There is also no rational basis for combining CFAD’s references, as
`
`they are directed to different endeavors. Ground 2 does not warrant an IPR trial of
`
`the ’720 patent.
`
`Fourth, CFAD’s Petition is an improper use of the IPR proceedings.
`
`Specifically, CFAD and the RPI are abusing and misusing the IPR process in an
`
`attempt to effectuate changes in the stock prices of the targeted innovator
`
`pharmaceutical companies. The self-serving actions of the RPI create unwarranted
`
`burdens for both patent owners and the Board. The Board should exercise its
`
`discretion under 35 U.S.C. §§ 314(a) and 316(b) and deny the Petition.1
`
`Fifth and finally, the Petition should also be denied because it fails to name
`
`all RPI—a threshold requirement for an IPR. Specifically omitted from the RPI
`
`identification are the investors in the Hayman funds responsible for filing the
`
`Petition. Having failed to name all RPI, the Petition cannot be considered.
`
`II. BACKGROUND
`
`Celgene is a biopharmaceutical company that is committed to improving the
`
`lives of patients through research and development of drug products that treat
`
`
`
`
`1 With the Board’s permission, Celgene has separately moved to dismiss the
`
`Petition pursuant to 37 C.F.R. § 42.12.
`
`04841.00006/7046102.1
`
`- 3 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`cancers and other devastating conditions. Three drug products developed by
`
`Celgene are relevant to this IPR: Thalomid®, Revlimid®, and Pomalyst®.
`
`Thalomid® is approved for the treatment of (1) erythema nodosum leprosum
`
`(“ENL”)—an inflammatory condition associated with leprosy; and (2) newly
`
`diagnosed multiple myeloma (“MM”) (in combination with dexamethasone). Ex.
`
`2001 at 1. The active ingredient in Thalomid® is thalidomide, which is well known
`
`for its teratogenicity (or ability to cause severe birth defects). Unfortunately, as
`
`described in more detail below, the devastating effects of thalidomide were felt
`
`worldwide during the thalidomide tragedy of the 1950s and 1960s, and continue
`
`today for the surviving victims. See, e.g., Ex. 2002 at 1; Ex. 1001 at 1:40-45.
`
`Revlimid® is approved for the treatment of (1) transfusion-dependent anemia
`
`due to low- or intermediate-1-risk myelodysplastic syndromes associated with a
`
`deletion 5q abnormality with or without additional cytogenetic abnormalities;
`
`(2) MM (in combination with dexamethasone); and (3) mantle cell lymphoma in
`
`certain patients whose disease has relapsed or progressed after two prior therapies.
`
`Ex. 2003 at 1. Pomalyst® (in combination with dexamethasone) is approved for
`
`the treatment of MM in patients who have received at least two prior therapies and
`
`whose disease has progressed. Ex. 2004 at 1. The active ingredient in Revlimid®
`
`is lenalidomide, and the active ingredient in Pomalyst® is pomalidomide. Ex. 2003
`
`at 1; Ex. 2004 at 1. According to the FDA-approved package inserts, lenalidomide
`
`04841.00006/7046102.1
`
`- 4 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`and pomalidomide are “thalidomide analogue[s],” and if these drugs are “used
`
`during pregnancy, [they] may cause birth defects or embryo-fetal death.” Ex. 2003
`
`at 1, 3, 7, 22-23; Ex. 2004 at 1, 2, 4, 14, 24. As described herein, due in large
`
`measure to the inventions claimed in the ’720 patent (and other of Celgene’s
`
`patents), Celgene’s FDA-approved systems for preventing fetal exposure to the
`
`active ingredients in Thalomid®, Revlimid®, and Pomalyst® have been 100%
`
`successful in preventing drug-related birth defects.
`
`A. The Challenge of Protecting A Fetus From A Teratogenic
`Drug While Allowing A Patient Access to Its Efficacy
`
`Beginning in 1958, thalidomide was marketed in Europe as a sedative and a
`
`treatment for pregnant women with morning sickness. See Ex. 1001 at 1:40-45;
`
`Ex. 2002 at 1. Shortly after entering the European market, it was discovered that
`
`thalidomide caused deformities in children born to mothers who had taken the drug
`
`during pregnancy. Id. As a result, by 1962, thalidomide had been withdrawn from
`
`all markets. Id. By then, the damage had been done. Thalidomide had been
`
`linked to more than 10,000 birth defects in at least 46 countries. Id. The birth
`
`defects were severe. Some children were born with missing or abnormal limbs,
`
`feet, or hands, a condition known as phocomelia (from the Greek for “seal”
`
`“limb”). Id. Many other deformities and complications were linked to
`
`thalidomide, including abnormal or absent ears, and heart and kidney problems.
`
`Id. As a result of this tragedy, drug regulatory authorities worldwide, including the
`
`04841.00006/7046102.1
`
`- 5 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`FDA, revised their regulations to ensure that new drugs were screened for safety in
`
`addition to efficacy, and were specifically investigated for their potential to cause
`
`harm to a developing fetus. Id.; Ex. 2005.
`
`Years later, it became clear that despite its teratogenicity, thalidomide had
`
`the power to benefit certain patient populations. Ex. 1001 at 1:46-62.
`
`Accordingly, Celgene believed it would be beneficial if the drug were made
`
`available to those patient populations. Due to its known teratogenicity, however,
`
`Celgene realized that to market thalidomide, it needed to develop a system that
`
`would allow patients in need of thalidomide to access it while ensuring that no
`
`thalidomide-related birth defects would occur. Ex. 1001 at 1:59-64.
`
`In other words, Celgene was faced with a great challenge—find a way to
`
`effectively avoid the teratogenic side effects of thalidomide while still making the
`
`drug available to patients in need. Indeed, Celgene recognized that it would need
`
`to create a system that was so effective at preventing birth defects of the type
`
`associated with teratogenic drugs that it would convince skeptical FDA regulators,
`
`and understandably vocal and concerned thalidomide victims around the world,
`
`that Thalomid® could be safely marketed. In other words, the new system would
`
`need to convince the FDA to lift its nearly 40-year ban on thalidomide.
`
`Celgene rose to meet this challenge, first developing the methods claimed in
`
`U.S. Patent No. 6,045,501 (the “Elsayed ’501 patent”) (Ex. 1003) (described in
`
`04841.00006/7046102.1
`
`- 6 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`Celgene’s Preliminary Response to IPR2015-01092). Celgene then improved upon
`
`its own work by inventing the methods claimed in the ’720 patent (described
`
`below). In other words, Celgene’s inventions for controlling access to thalidomide
`
`(and other teratogens) came in two phases. Celgene first developed S.T.E.P.S.®,
`
`which is claimed in the Elsayed ’501 patent and was first implemented with the
`
`July 1998 Thalomid PI. The initial implementation of S.T.E.P.S.® only
`
`retrospectively identified patient behaviors that posed a risk of fetal exposure to
`
`thalidomide. See Ex. 2006 at 328. While this patented system was 100%
`
`successful in preventing birth defects of the type associated with thalidomide in
`
`patients taking Thalomid®, Celgene (and the inventors of the ’720 patent) still saw
`
`room for significant improvement.
`
`Thus, the ’720 patent’s inventors developed changes that transformed
`
`S.T.E.P.S.® from a retrospective program into a prospective program called
`
`Enhanced S.T.E.P.S.® See id. Specifically, from October 1999 to September
`
`2001, the inventors focused on implementing changes that were “designed to
`
`identify patients exhibiting behaviours providing risk for fetal exposure and to
`
`remedy those behaviours prior to dispensing thalidomide.” Id. (emphasis added).
`
`04841.00006/7046102.1
`
`- 7 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`PROTECTIVE ORDER MATERIAL
`
`IPR20l5-01096
`Patent 6,315,720
`
`As explained in the ’720 patent, the inventors
`
`came up with the authorization process of Enhanced S.T.E.P.S.®, which
`
`involves generating a prescription approval code to be retrieved by the
`
` pharmacy. Ex. 1001 at 13:43-45.
`
`Enhanced S.T.E.P.S.® was implemented for the first time with the September
`
`2001 Thalomid® package insert (“September 2001 Thalomid PI”), which is not
`
`prior art to the 720 patent. See Ex. 2008. Specifically, the September 2001
`
`Thalomid PI included the significant improvements claimed in the ‘720 patent.
`
`Those improvements are reflected in the September 2001 revisions to July 1998
`
`Thalomid PI, which CFAD relies upon here. For example:
`
`048-11.00006/7046l0’2.l
`
`- 8 -
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`DRUG MUST ONLY BE DISPENSED IN NO MORE THAN A 1
`
`MONTH SUPPLY AND ONLY ON PRESENTATION OF A NEW
`
`PRESCRIPTION WRITTEN WITHIN THE PREVIOUS 7 DAYS.
`
`SPECIFIC INFORMED CONSENT (copy attached as part of this
`
`package insert) AND COMPLIANCE WITH THE MANDATORY
`
`PATIENT REGISTRY AND SURVEY ARE REQUIRED FOR ALL
`
`PATIENTS (MALE AND FEMALE) PRIOR TO DISPENSING BY
`
`THE PHARMACIST.
`
`BEFORE DISPENSING THALOMID® (thalidomide), YOU MUST
`
`ACTIVATE THE AUTHORIZATION NUMBER ON EVERY
`
`PRESCRIPTION BY CALLING THE CELGENE CUSTOMER
`
`CARE CENTER AT 1-888-4-CELGENE (1-888-423-5436) AND
`
`OBTAINING A CONFIRMATION NUMBER. YOU MUST ALSO
`
`WRITE THE CONFIRMATION NUMBER ON THE
`
`PRESCRIPTION. YOU SHOULD ACCEPT A PRESCRIPTION
`
`ONLY IF IT HAS BEEN ISSUED WITHIN THE PREVIOUS 7
`
`DAYS (TELEPHONE PRESCRIPTIONS ARE NOT PERMITTED);
`
`DISPENSE NO MORE THAN A 4-WEEK (28- DAY) SUPPLY,
`
`WITH NO AUTOMATIC REFILLS; DISPENSE BLISTER PACKS
`
`INTACT (CAPSULES CANNOT BE REPACKAGED); DISPENSE
`
`SUBSEQUENT PRESCRIPTIONS ONLY IF FEWER THAN 7
`
`DAYS OF THERAPY REMAIN ON THE PREVIOUS
`
`PRESCRIPTION; AND EDUCATE ALL STAFF PHARMACISTS
`
`ABOUT THE DISPENSING PROCEDURE FOR THALOMID®
`
`(thalidomide).
`
`Ex. 2009 at 4; see Ex. 2008 at 20.
`
`04841.00006/7046102.1
`
`- 9 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`IPR2015-01096
`
`Patent Owner Preliminary Response
` Patent 6,315,720
`
`
`
`
`
`
`
`
`
`
`Today, Enhanced S.T.E.P.S.® is known as the Thalomid REMS, which is an
`
`FDA-approved Risk Evaluation and Mitigation Strategy (“REMS”). Enhanced
`
`S.T.E.P.S.® is claimed in Jepson format in the ’720 patent as an improvement over
`
`S.T.E.P.S.®, which was originally claimed in the ’501 patent. Celgene’s continued
`
`success in preventing birth defects due to Thalomid®, Revlimid®, and Pomalyst® is
`
`in large measure due to the inventions of the ’720 patent and other Celgene patents
`
`(including the ’501 patent). Had Celgene not developed the claimed methods for
`
`preventing fetal exposure to teratogenic (or potentially teratogenic) drugs,
`
`Thalomid®, Revlimid®, and Pomalyst® would not be available to patients today.
`
`The FDA first approved Thalomid® for the treatment of ENL in July 1998
`
`subject to 21 CFR § 314.520 (“Subpart H”), which allowed the FDA to approve
`
`drugs that were shown to be effective, but that could only be used safely under
`
`restricted conditions. Ex. 1025 at 0002. Specifically, the approval letter stated that
`
`Thalomid® was being approved because Celgene presented adequate information
`
`to demonstrate that the drug would be safe and effective for use when marketed
`
`under S.T.E.P.S.®, which is an embodiment of the methods described in Celgene’s
`
`patents. Id. The FDA subsequently approved Celgene’s labeling changes that
`
`incorporated the improvements of Enhanced S.T.E.P.S.®, which is an embodiment
`
`of the methods described in the ’720 patent. See Ex. 2009 at 4; Ex. 2008 at 20.
`
`Then, when Thalomid® was approved for the treatment of newly diagnosed MM in
`
`04841.00006/7046102.1
`
`- 10 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`2006, the FDA maintained the same restrictions on distribution of the drug. Ex.
`
`2010 at 1. Similarly, the FDA conditioned its approval of both Revlimid® and
`
`Pomalyst® (for all indications), on Celgene’s use of the same restrictions applied to
`
`Thalomid®. Ex. 2011 at 1; Ex. 2012 at 7-10.
`
`B.
`
`Previous Attempts to Control Access to
`Other Drugs Were Unsuccessful
`
`Others attempted to control access to the drugs Accutane® (isotretinoin) and
`
`Clozaril® (clozapine) before Celgene invented S.T.E.P.S.®, but as described below,
`
`those attempts failed to meet their goals. Both failed to provide a workable
`
`solution for dealing with a drug like thalidomide, where even a single drug-related
`
`birth defect was unacceptable.
`
`Accutane® contains isotretinoin, a form of vitamin A (a vitamin A analogue)
`
`that has been used as a treatment for severe cystic acne since 1982. Ex. 1011 at
`
`101. Isotretinoin can and has caused birth defects in children whose mothers are
`
`taking the drug. Id. Because of the teratogenic effects of isotretinoin, and instead
`
`of removing the drug from the market, the manufacturer of isotretinoin
`
`implemented the Pregnancy Prevention Program (“PPP”).
`
`The PPP, however, was not effective in preventing women who were taking
`
`Accutane® from becoming pregnant or from exposing fetuses to isotretinoin. In
`
`fact, the Mitchell reference that CFAD relies upon (Ex. 1011) discloses that there
`
`were more than 400 pregnancies that occurred during isotretinoin treatment, at
`
`04841.00006/7046102.1
`
`- 11 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`least six of which resulted in live born infants with at least minor anomalies, and at
`
`least one with major anomalies. Id. at 103-04. Mitchell further reports that in the
`
`first several months of the PPP, there was incomplete compliance with several
`
`parts of the program, such as failures to ensure negative pregnancy tests before
`
`beginning treatment, failures to wait until menses begins before treatment, and
`
`failures to use effective birth control before, during, and after treatment. Id. at 104.
`
`Compliance remained incomplete even after the manufacturer changed the
`
`medication package to highlight the most important parts of the PPP. Id.
`
`Publications in prominent scientific journals also disparaged the PPP. For
`
`instance, an article in the New England Journal of Medicine reported that “[s]ince
`
`the [PPP] was implemented in 1989, a substantial number of fetuses have been
`
`exposed to the drug. As many as 30 percent of the women with exposed fetuses
`
`did not use any mode of contraception, even though they were cognizant of the
`
`high fetal risk.” Ex. 2013 at 1130.
`
`Clozaril® contains clozapine, and is used to treat schizophrenia. Ex. 1008 at
`
`899. Its release into the market was permitted only with certain prescribing and
`
`distribution restrictions implemented by the manufacturer. Id. These restrictions
`
`were put in place because the use of clozapine is associated with a high frequency
`
`of agranulocytosis, a potentially fatal blood disorder. Ex. 2014 at 52. Clozapine is
`
`not a teratogenic drug—it does not cause birth defects—and the system employed
`
`04841.00006/7046102.1
`
`- 12 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`to monitor its use was not tailored to restrict or prevent birth defects. Instead, the
`
`manufacturer developed a program called the Clozaril National Registry to
`
`“enhance patient safety by facilitating early detection of potentially dangerous
`
`white blood cell suppression.” Id. at 52-53. But like the PPP, the clozapine system
`
`was also a failure. Specifically, during its first five years, 382 patients developed
`
`agranulocytosis, and 12 of those patients died as a result. Id. at 55.
`
`When Celgene invented S.T.E.P.S.® and the methods claimed in the ’501
`
`patent, the programs in place for both the Accutane® and Clozaril® were
`
`ineffective. The ’501 patent was a significant innovation over those systems and,
`
`as noted above, the ’720 patent was a significant improvement over the ’501
`
`patent. To date, Celgene’s FDA-approved systems for preventing fetal exposure to
`
`the active ingredients in Thalomid®, Revlimid®, or Pomalyst®—all of which are
`
`covered by the claims of the ’720 patent—have been 100% successful in
`
`preventing birth defects of the type associated with thalidomide. Celgene’s
`
`patented methods were so successful that, in 2006, it became clear that the PPP
`
`(and later attempts at managing the distribution of isotretinoin) were ineffective by
`
`comparison. Consequently, the FDA required the manufacturers of isotretinoin to
`
`use Celgene’s patented methods if they wanted to keep their products on the
`
`market. This resulted in licenses to several of Celgene’s patents, including the
`
`04841.00006/7046102.1
`
`- 13 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`’720 patent, in connection with the distribution of isotretinoin under a program
`
`known as iPledge. See Ex. 2015 at 11; Ex. 2016 at 1; and Ex. 2017 at 6.
`
`C. The ’720 Patent
`
`As discussed above, the ’720 patent describes and claims improved methods
`
`for delivering a potentially dangerous drug to a patient (including teratogenic drugs
`
`such as thalidomide) while avoiding the occurrence of adverse side effects (such as
`
`birth defects). See Ex. 1001 at Abstract; 1:8-16. The claims are set forth in Jepson
`
`format, with a preamble comprising a general description of the known elements of
`
`the claimed invention (which are claimed in the Elsayed ’501 patent, and embodied
`
`in S.T.E.P.S.® and the July 1998 Thalomid PI), and the novel improved elements
`
`(which are embodied in Enhanced S.T.E.P.S.® and the September 2001 Thalomid
`
`PI) set forth after the “improvement comprising” clause. See 37 C.F.R. § 1.75(e)
`
`(describing the preferred format for claims to improvements). For example,
`
`independent Claim 1 of the ’720 patent recites:
`
`In a method for delivering a drug to a patient in need of the drug,
`
`while avoiding the occurrence of an adverse side effect known or
`
`suspected of being caused by said drug, wherein said method is of the
`
`type in which prescriptions for said drug are filled only after a
`
`computer readable storage medium has been consulted to assure that
`
`the prescriber is registered in said medium and qualified to prescribe
`
`said drug, that the pharmacy is registered in said medium and
`
`qualified to fill the prescription for said drug, and the patient is
`
`04841.00006/7046102.1
`
`- 14 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`registered in said medium and approved to receive said drug, the
`
`improvement comprising:
`a. defining a plurality of patient risk groups based upon a predefined
`
`set of risk parameters for said drug;
`b. defining a set of information to be obtained from said patient,
`
`which information is probative of the risk that said adverse side
`
`effect is likely to occur if said drug is taken by said patient;
`c. in response to said information set, assigning said patient to at least
`
`one of said risk groups and entering said risk group assignment in
`
`said medium;
`d. based upon said information and said risk group assignment,
`
`determining whether the risk that said adverse side effect is likely
`
`to occur is acceptable; and
`e. upon a determination that said risk is acceptable, generating a
`
`prescription approval code to be retrieved by said pharmacy before
`
`said prescription is filled.
`
`Ex. 1001 at Claim 1. The only other independent claim, Claim 28, includes all of
`
`the elements of Claim 1 and adds the following further limitation: “wherein said
`
`adverse side effect is likely to arise in patients who take said drug in combination
`
`with at least one other drug.” Id. at Claim 28. The dependent claims further limit
`
`and define the controls to avoid adverse side effects. See id. at Claims 2-27, 29-32.
`
`During prosecution, the Examiner extensively considered the most
`
`significant prior art, namely the ’501 patent (also known as “Elsayed”), and
`
`concluded that it did not disclose, teach, or suggest the ’720 patent’s inventions.
`
`04841.00006/7046102.1
`
`- 15 -
`
`
`
`PROTECTIVE ORDER MATERIAL
`
`
`
`Patent Owner Preliminary Response
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`IPR2015-01096
` Patent 6,315,720
`
`Specifically, the Examiner found that “Elsayed et al. teaches a method for
`
`delivering a drug to a patient while preventing the exposure to a fetus or to other
`
`individuals with contraindications to the drug that includes registering prescribers,
`
`pharmacists, and patients in a computer readable storage medium for authorizing
`
`and monitoring distribution of the drug,” but noted that Elsayed “does not teach a
`
`step of generating of a prescription number or code, which can be retrieved by a
`
`pharmacy before said prescription is filled.” Ex. 1002 at 0091 (emphasis added).
`
`In other words, the Examiner concluded that the Elsayed ’501 patent disclosed
`
`only what was in the preamble of the ’720 patent’s Jepson claims, but did not
`
`disclose, teach, or suggest the claimed improvements, which were